Target intelligence / Profile preview

Siderocalin (NGAL; Scn)

Target
NGAL; Scn
Molecular classification
Protein, Lipocalin family, Immune effector protein, Iron-sequestering protein, Siderophore-binding protein
01

Overview

Siderocalin (Lipocalin-2, NGAL, 24p3) is a mammalian immune protein of the lipocalin family, playing a vital role in host defense by binding and sequestering iron-chelating siderophores. This activity restricts iron availability to invading bacteria, acting as a bacteriostatic mechanism in the innate immune response. The protein is structurally characterized by a cup-shaped binding domain ("calyx") with three positively charged pockets that accommodate the catecholate groups of siderophores, particularly those like enterobactin from *Escherichia coli* and bacillibactin from *Bacillus anthracis*. Siderocalin can also bind a variety of other ferric complexes and is found in monomeric, dimeric, or trimeric forms in plasma. Its selectivity is defined by shape and charge complementarity with specific bacterial siderophores, and bacteria may evade its binding by chemically modifying their siderophores. Siderocalin is used clinically as a biomarker of kidney injury, and altered levels are associated with infection, inflammation, and cancer prognosis. Although not currently a direct drug target, its mechanism of iron sequestration is a focus of research in antimicrobial and diagnostic development.

Other names
Lipocalin-2NGAL24p3Neutrophil gelatinase-associated lipocalinScn
02

Mechanism of action

Sequestration of iron by binding ferric siderophore complexes, inhibiting bacterial iron acquisition Potential anti-infective mechanisms by starving pathogens of iron

03

Biological functions

Innate immune responseIron homeostasisAntibacterial defense (by siderophore sequestration)Transport of small molecules
04

Disease associations

Infection (bacterial, especially by enteric bacteria and mycobacteria)Cancer (various roles in tumorigenesis and prognosis)InflammationKidney disease (acute kidney injury marker)Other (roles in metabolic and cardiovascular diseases under investigation)
05

Safety considerations

Potential immune activation or interference with iron homeostasis if dysregulatedOff-target effects of iron sequestration could theoretically impact human cell iron levels, but no direct clinical toxicity is established for endogenous siderocalin
06

Interacting drugs

No approved drugs directly targeting Siderocalin; iron chelators (siderophores) and related molecules may interact, but therapeutic targeting is under investigation
07

Biomarkers

Neutrophil gelatinase-associated lipocalin (NGAL) is a validated biomarker for acute kidney injuryNGAL levels used in monitoring infection and inflammation

Beyond the preview

Go deeper on Siderocalin (NGAL; Scn).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Siderocalin (NGAL; Scn).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call